| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6831b19bfc354357342f7c7da79fc162 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2001-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c9ab92751f97e7b31057da81dbf3d02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_606f74787d7808a054d41e3d56f744a3 |
| publicationDate |
2003-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1316316-A1 |
| titleOfInvention |
Preparations for oral administration |
| abstract |
The present invention provides a preparation for oralnadministration containing a medicinal substance havingncGMP-specific phosphodiesterase inhibitory activity andnshowing decrease of solubility in the neutral and alkalinenregions, wherein an acidic substance is compounded promotenthe dissolution of the medicinal substance in digestiventract and thus the efficacy can be expressed at the earlynstage after administration, and which preparation is usefulnin treatment of erectile dysfunction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2213306-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2213306-A4 |
| priorityDate |
2000-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |